Afficher la notice abrégée

dc.contributor.authorGarcía-Tuñón, Ignacio
dc.contributor.authorAlonso-Pérez, Verónica
dc.contributor.authorVuelta Ramos, Elena 
dc.contributor.authorPérez- Ramos, Sandra
dc.contributor.authorHerrero García, María 
dc.contributor.authorMéndez, Lucía
dc.contributor.authorHernández Sánchez, Jesús María 
dc.contributor.authorMartín Izquierdo, Marta
dc.contributor.authorSaldaña, Raquel
dc.contributor.authorSevilla, Julián
dc.contributor.authorSánchez Guijo Martín, Fermín 
dc.contributor.authorHernández Rivas, Jesús María 
dc.contributor.authorSánchez Martín, Manuel Adolfo 
dc.date.accessioned2021-05-25T07:20:03Z
dc.date.available2021-05-25T07:20:03Z
dc.date.issued2019
dc.identifier.citationGarcía-Tuñón I, Alonso-Pérez V, Vuelta E, Pérez- Ramos S, Herrero M, Méndez L, et al. (2019) Splice donor site sgRNAs enhance CRISPR/ Cas9-mediated knockout efficiency. PLoS ONE 14 (5): e0216674. https://doi.org/10.1371/journal. pone.0216674es_ES
dc.identifier.urihttp://hdl.handle.net/10366/146291
dc.description.abstract[EN]CRISPR/Cas9 allows the generation of knockout cell lines and null zygotes by inducing site-specific double-stranded breaks. In most cases the DSB is repaired by non-homologous end joining, resulting in small nucleotide insertions or deletions that can be used to construct knockout alleles. However, these mutations do not produce the desired null result in all cases, but instead generate a similar, functionally active protein. This effect could limit the therapeutic efficiency of gene therapy strategies based on abrogating oncogene expression, and therefore needs to be considered carefully. If there is an acceptable degree of efficiency of CRISPR/Cas9 delivery to cells, the key step for success lies in the effectiveness of a specific sgRNA at knocking out the oncogene, when only one sgRNA can be used. This study shows that the null effect could be increased with an sgRNA targeting the splice donor site (SDS) of the chosen exon. Following this strategy, the generation of null alleles would be facilitated in two independent ways: the probability of producing a frameshift mutation and the probability of interrupting the canonical mechanism of pre-mRNA splicing. In these contexts, we propose to improve the loss-of-function yield driving the CRISPR system at the SDS of critical exons.es_ES
dc.format.mimetypeapplication/pdf
dc.language.isoenges_ES
dc.publisherStefan Maas, National Institutes of Health, UNITED STATESes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCRISPR/Cas9es_ES
dc.subjectDonores_ES
dc.subjectsgRNAses_ES
dc.subjectCell lineses_ES
dc.subjectGenomees_ES
dc.subjectNucleotidees_ES
dc.subjectGene therapyes_ES
dc.subject.meshCRISPR-Cas Systems*
dc.subject.meshCell Line*
dc.subject.meshGenome*
dc.titleSplice donor site sgRNAs enhance CRISPR/Cas9-mediated knockout efficiencyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.1371/journal.pone.0216674es_ES
dc.subject.unesco2409 Genéticaes_ES
dc.identifier.doi10.1371/journal.pone.0216674
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.essn1932-6203
dc.journal.titlePLOS ONEes_ES
dc.volume.number14es_ES
dc.issue.number5es_ES
dc.page.initiale0216674es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decsgenoma*
dc.subject.decslínea celular*
dc.subject.decssistemas CRISPR-Cas*


Fichier(s) constituant ce document

Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Attribution-NonCommercial-NoDerivatives 4.0 Internacional